The axis AGE-RAGE-soluble RAGE and oxidative stress in chronic kidney disease (Q38231271)

31 August 2017

The axis AGE-RAGE-soluble RAGE and oxidative stress in chronic kidney disease (English)

1 reference

31 August 2017

Alejandro Gugliucci

1

1 reference

PubMed ID

25039001

31 August 2017

Teresita Menini

series ordinal

2

1 reference

PubMed ID

25039001

31 August 2017

language of work or name

English

0 references

publication date

1 January 2014

1 reference

Advances in Experimental Medicine and Biology

31 August 2017

1 reference

31 August 2017

824

1 reference

31 August 2017

191-208

1 reference

Skin autofluorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic kidney disease

31 August 2017

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

AGEs/RAGE in CKD: irreversible metabolic memory road toward CVD?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Targeting the AGE-RAGE axis improves renal function in the context of a healthy diet low in advanced glycation end-product content

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Advanced glycation end products, oxidative stress and diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Atherosclerosis and diabetes: the RAGE connection

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Advanced glycation end products and the progressive course of renal disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Protein glycation in the kidney: role in diabetes and aging

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

The Maillard reaction in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Advanced glycation end products in renal failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Glycation free adduct accumulation in renal disease: the new AGE.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Glyoxalase-1 overexpression reduces endothelial dysfunction and attenuates early renal impairment in a rat model of diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Reaction of advanced glycation endproducts with renal tissue from normal and streptozotocin-induced diabetic rats: an ultrastructural study using colloidal gold cytochemistry

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Oxidative stress in patients with cardiovascular disease and chronic renal failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

The next generation of RAGE modulators: implications for soluble RAGE therapies in vascular inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Advanced glycation endproducts: from precursors to RAGE: round and round we go.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Accumulation of Maillard reaction products in skin collagen in diabetes and aging

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Role of glycation in aging

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Tobacco smoke is a source of toxic reactive glycation products

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Highlights and hotspots of protein glycation in end-stage renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Effects of kidney or kidney-pancreas transplantation on plasma pentosidine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Profound mishandling of protein glycation degradation products in uremia and dialysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Accumulation of free adduct glycation, oxidation, and nitration products follows acute loss of renal function

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Role of advanced glycation endproducts and potential therapeutic interventions in dialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Systemic and local impact of glucose and glucose degradation products in peritoneal dialysis solution

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Serum advanced glycosylation end products: a new class of uremic toxins?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Oxidative stress and advanced glycation in diabetic nephropathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyl

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

RAGE: a novel cellular receptor for advanced glycation end products

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Enhanced RAGE-mediated NFkappaB stimulation in inflamed hemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Renal microvascular injury in diabetes: RAGE and redox signaling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

The receptor of advanced glycation end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Interaction of receptor for advanced glycation end products with advanced oxidation protein products induces podocyte injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

RAGE, glomerulosclerosis and proteinuria: roles in podocytes and endothelial cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

RAGE and the pathogenesis of chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Receptor for advanced glycation end products--soluble form and gene polymorphisms in chronic haemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD).

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: New Roles for Soluble RAGE.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Soluble forms of RAGE in internal medicine.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Calcitriol treatment increases serum levels of the soluble receptor of advanced glycation end products in hemodialysis patients with secondary hyperparathyroidism.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Serum S100A12 (EN-RAGE) Levels in Patients with Decreased Renal Function and Subclinical Chronic Inflammatory Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Circulating soluble RAGE increase after a cerebrovascular event.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Receptor for advanced glycation end products (RAGE), inflammatory ligand EN-RAGE and soluble RAGE (sRAGE) in subjects with Takayasu's arteritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Soluble RAGE plasma levels in patients with coronary artery disease and peripheral artery disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Relationship of Soluble RAGE and RAGE Ligands HMGB1 and EN-RAGE to Endothelial Dysfunction in Type 1 and Type 2 Diabetes Mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Differential effects of advanced glycation end-products on renal tubular cell inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Discordant effects of rosiglitazone on novel inflammatory biomarkers

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Soluble RAGE-modulating drugs: state-of-the-art and future perspectives for targeting vascular inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Advanced glycation end-products: implications for diabetic and non-diabetic nephropathies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Targeted reduction of advanced glycation improves renal function in obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Advanced glycation end-products and the kidney

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Endogenous secretory receptor for advanced glycation end-products and cardiovascular disease in end-stage renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

A severe diabetic nephropathy model with early development of nodule-like lesions induced by megsin overexpression in RAGE/iNOS transgenic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Skin autofluorescence is associated with the progression of chronic kidney disease: a prospective observational study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Convective therapies versus low-flux hemodialysis for chronic kidney failure: a meta-analysis of randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Advanced glycation end products, aortic stiffness, and wave reflection in peritoneal dialysis as compared to hemodialysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Tissue advanced glycation end product deposition after kidney transplantation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Skin autofluorescence as a marker of cardiovascular risk in children with chronic kidney disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Ilex paraguariensis extracts inhibit AGE formation more efficiently than green tea.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Caffeic and chlorogenic acids in Ilex paraguariensis extracts are the main inhibitors of AGE generation by methylglyoxal in model proteins.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

The polyamines spermine and spermidine protect proteins from structural and functional damage by AGE precursors: a new role for old molecules?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

The botanical extracts of Achyrocline satureoides and Ilex paraguariensis prevent methylglyoxal-induced inhibition of plasminogen and antithrombin III.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Characterization of phenolics, in vitro reducing capacity and anti-glycation activity of red grape skins recovered from winemaking by-products

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Prevention of non-enzymic glycation of proteins by dietary agents: prospects for alleviating diabetic complications

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Green tea polyphenol epigallocatechin-3-gallate inhibits advanced glycation end product-induced expression of tumor necrosis factor-alpha and matrix metalloproteinase-13 in human chondrocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Effect of green tea extract on advanced glycation and cross-linking of tail tendon collagen in streptozotocin induced diabetic rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Current therapeutic interventions in the glycation pathway: evidence from clinical studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Methylglyoxal and advanced glycation endproducts: new therapeutic horizons?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

The role of AGEs and AGE inhibitors in diabetic cardiovascular disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Cross-link breakers as a new therapeutic approach to cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

The multifaceted therapeutic potential of benfotiamine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Effects of thiamine and benfotiamine on intracellular glucose metabolism and relevance in the prevention of diabetic complications

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

New potential agents in treating diabetic kidney disease: the fourth act.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-07320-0_14

10.1007/978-3-319-07320-0_14

31 March 2020

Identifiers

DOI

1 reference

31 August 2017

1 reference

PubMed ID

25039001